NCT05265429 Biology of Young Lung Cancer Study: The YOUNG LUNG Study
| NCT ID | NCT05265429 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dana-Farber Cancer Institute |
| Condition | Non Small Cell Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2023-01-01 |
| Primary Completion | 2027-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2023-01-01 with a primary completion date of 2027-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research study is to learn more about lung cancer (NSCLC or SCLC) diagnosed in adults at ages 45 or younger.
Eligibility Criteria
Inclusion Criteria: * Age 45 and under at lung cancer diagnosis * Pathologically confirmed bronchogenic lung carcinoma (NSCLC or SCLC of any stage) at any treatment time point * Provision of written informed consent * Willingness to undergo no more than two (2) peripheral blood draws in a four (4) week period, with no more than 50 ml peripheral blood collected over eight (8) weeks * Individuals under age 18 are eligible for study if they meet defined criteria; in addition, consent for participation must be given by a legal guardian or parent Exclusion Criteria: * Individuals who decline to sign consent * Individuals who are unable to give consent or assent and are without a designated healthcare proxy * Compromise of patient diagnosis or staging if tissue is used for research
Contact & Investigator
Pasi A Janne, MD, PhD
PRINCIPAL INVESTIGATOR
Dana-Farber Cancer Institute
Frequently Asked Questions
Who can join the NCT05265429 clinical trial?
This trial is open to participants of all sexes, aged 15 Years or older, studying Non Small Cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05265429 currently recruiting?
Yes, NCT05265429 is actively recruiting participants. Contact the research team at Pasi_Janne@dfci.harvard.edu for enrollment information.
Where is the NCT05265429 trial being conducted?
This trial is being conducted at Boston, United States, Boston, United States, Boston, United States, Boston, United States.
Who is sponsoring the NCT05265429 clinical trial?
NCT05265429 is sponsored by Dana-Farber Cancer Institute. The principal investigator is Pasi A Janne, MD, PhD at Dana-Farber Cancer Institute. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.